Cetera Investment Advisers
CRSP icon

Cetera Investment Advisers’s CRISPR Therapeutics CRSP Stock Holding History

Cetera Investment Advisers’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.82M Sell
59,245
-4,668
-7% -$246K ﹤0.01% 1963
2025
Q4 		$3.35M Buy
63,913
+83
+0.1% +$4.97K ﹤0.01% 1761
2025
Q3 		$4.14M Buy
63,830
+15,815
+33% +$908K ﹤0.01% 1564
2025
Q2 		$2.34M Sell
48,015
-9,904
-17% -$383K ﹤0.01% 1727
2025
Q1 		$1.97M Buy
57,919
+28,084
+94% +$1.19M ﹤0.01% 1758
2024
Q4 		$1.17M Sell
29,835
-5,777
-16% -$273K ﹤0.01% 2056
2024
Q3 		$1.67M Buy
35,612
+8,774
+33% +$445K ﹤0.01% 1755
2024
Q2 		$1.45M Sell
26,838
-7,262
-21% -$420K ﹤0.01% 1808
2024
Q1 		$2.32M Buy
34,100
+27,915
+451% +$2M 0.01% 1437
2023
Q4 		$387K Buy
6,185
+440
+8% +$24.3K ﹤0.01% 1634
2023
Q3 		$261K Buy
5,745
+38
+0.7% +$1.96K ﹤0.01% 1823
2023
Q2 		$320K Sell
5,707
-2,519
-31% -$143K ﹤0.01% 1702
2023
Q1 		$372K Sell
8,226
-374
-4% -$18.2K ﹤0.01% 1580
2022
Q4 		$350K Buy
8,600
+1,957
+29% +$104K ﹤0.01% 1563
2022
Q3 		$434K Sell
6,643
-1,421
-18% -$103K 0.01% 1045
2022
Q2 		$490K Buy
8,064
+237
+3% +$13.9K 0.01% 1108
2022
Q1 		$491K Buy
7,827
+863
+12% +$54.2K 0.01% 1169
2021
Q4 		$528K Sell
6,964
-253
-4% -$22.1K 0.01% 1150
2021
Q3 		$808K Buy
7,217
+809
+13% +$102K 0.01% 861
2021
Q2 		$1.04M Buy
6,408
+1,786
+39% +$217K 0.02% 757
2021
Q1 		$563K Sell
4,622
-489
-10% -$73.8K 0.01% 908
2020
Q4 		$783K Buy
+5,111
New +$604K 0.02% 766

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GP
GSK plc London $599M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Cetera Investment Advisers's CRSP Position: Q1 2026 in Review

Cetera Investment Advisers reduced its CRISPR Therapeutics (CRSP) stake by 7.3% in Q1 2026, selling an estimated $246K and leaving 59,245 shares worth $2.82M. The position accounts for ﹤0.01% of the portfolio, ranked #1963.

Cetera Investment Advisers first reported a position in CRSP in Q4 2020 and has held it in 22 quarters since. The position peaked at $4.14M in Q3 2025. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • Cetera Investment Advisers held 59,245 shares of CRISPR Therapeutics worth $2.82M as of Q1 2026.
  • Cetera Investment Advisers sold 4,668 CRISPR Therapeutics shares in Q1 2026, an estimated $246K.
  • CRISPR Therapeutics made up ﹤0.01% of Cetera Investment Advisers's portfolio in Q1 2026, its #1963 holding.
  • Cetera Investment Advisers first reported a position in CRISPR Therapeutics in Q4 2020 and has held it in 22 quarters since.
  • Cetera Investment Advisers's CRISPR Therapeutics position peaked at $4.14M in Q3 2025.
  • 488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on Cetera Investment Advisers's 13F filing for Q1 2026, filed 13 May 2026.